ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

4:00PM-4:15PM: Abstract Number: 0817

More than 40% of Older Adults with Rheumatic Diseases Are Prescribed Opioid Medications

Abstracts: Pain in Rheumatic Disease Including Fibromyalgia (0813–0818)

4:00PM-4:15PM: Abstract Number: 0829

Multi-Center Use of an Online Case-Based Simulation to Evaluate Medical Trainee Use of Diagnostic Imaging and Lab Tests to Correctly Diagnose MSK Complaints

Abstracts: Professional Education (0825–0830)

4:15PM-4:30PM: Abstract Number: 0842

Association of urinary biomarkers with histological features in diagnostic and per-protocol repeat kidney biopsies in lupus nephritis

Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes I: Advances in Nephritis (0837–0842)

4:15PM-4:30PM: Abstract Number: 0824

Characterizing Immune Responses in Abatacept-treated Patients with Limited Juvenile Idiopathic Arthritis

Abstracts: Pediatric Rheumatology – Basic Science (0819–0824)

4:15PM-4:30PM: Abstract Number: 0836

Growth Differentiation Factor-15 Predicts Frailty and Death in Rheumatoid Arthritis

Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes II: Look What You Made Me Do (Prediction) (0831–0836)

4:15PM-4:30PM: Abstract Number: 0830

Rheum2Listen: Leveraging Podcasts to Teach Rheumatology to Internal Medical Residents

Abstracts: Professional Education (0825–0830)

4:15PM-4:30PM: Abstract Number: 0818

Risk of Cardiovascular Events is Higher in Pregabalin Users Versus Duloxetine: A Cohort Study Among Veterans with Chronic Musculoskeletal Pain

Abstracts: Pain in Rheumatic Disease Including Fibromyalgia (0813–0818)

4:15PM-4:30PM: Abstract Number: 0848

Spatial Frequency Domain Imaging (SFDI) for Skin Assessment in Systemic Sclerosis: Insights from Histology and Clinical Correlates

Abstracts: Systemic Sclerosis & Related Disorders – Clinical I (0843–0848)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].